Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Market Snapshot: Under Pressure, Insulin Makers Pin Hopes On New Products

Executive Summary

Bevy of new products like Novo Nordisk’s Tresiba offer some incremental improvements over older insulins, but in an increasingly crowded market, payers have the upper hand.


Related Content

UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
Lilly and Boehringer Ingelheim Launch Biosimilar Lantus In UK, Germany
Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst